Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Animal-Free Derived Collagen-Like Protein Based Electrospun Nanofibers for Biomedical Applications: Cell Interactions Studies

Krauss C., Montero Mirabet M., Thaqi BS., Weber S., Mäder K.

Animal Study on Chronic Wound, published in Macromol Biosci (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Macromol Biosci (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41954887
PMCID
PMC13064797
DOI
10.1002/mabi.70180

Abstract (original English)

Biocompatibility of biomaterials is essential for their application in the biomedical field, particularly in tissue engineering and drug delivery systems. This study focuses on VECOLLAN, a recombinant, non-animal-derived collagen-like protein (CLP), which exhibits excellent biocompatibility while promoting in vitro cell proliferation and wound healing. We previously optimized electrospinning parameters and employed a coaxial crosslinking approach to produce VECOLLAN-based fibers with tunable dissolution, swelling behavior, and elasticity suitable for biomedical applications. The current study aims to assess the compatibility of these fibers with cells (NIH/3T3), investigate chemical leachables from three different formulations of DMTMM cross-linked VECOLLAN-fibers (according to ISO 10993-18), and conduct spectroscopic analysis to confirm crosslinking efficacy. Results indicate that most CLP-based nonwoven mats maintained cell viability above the 70% safety threshold as per ISO-10993-5. The sample with a CLP:DMTMM ratio of 1:0.1 demonstrated the most favorable cell compatibility and effective crosslinking. While the coaxial crosslinking method showed efficiency, residual crosslinker molecules and unexpected derivatives are identified. Spectroscopic investigations gave hints of successful crosslinking, although a direct correlation between crosslinker concentration and spectral b

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
NIH 3T3 CellsAnimalsMiceCollagenBiocompatible MaterialsCross-Linking ReagentsTissue EngineeringMaterials TestingCell ProliferationCell Survival

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research